Freund's adjuvant, NOD2 and mycobacteria

Current Opinion in Microbiology

Volumn 23, Issue , 2015, Pages 126-132

  Behr, Marcel A ^a,b   Divangahi, Maziar ^a,b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; FREUND ADJUVANT; MURAMYL DIPEPTIDE; N GLYCOLOYLNEURAMINIC ACID; PEPTIDOGLYCAN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; NOD2 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; MYCOBACTERIUM TUBERCULOSIS; REVIEW; SYNTHESIS; TUBERCULOSIS; CELL WALL; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; CELL WALL; FREUND'S ADJUVANT; IMMUNITY, INNATE; MYCOBACTERIUM TUBERCULOSIS; NOD2 SIGNALING ADAPTOR PROTEIN; PEPTIDOGLYCAN; T-LYMPHOCYTES;

EID: 84916882574     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2014.11.015     Document Type: Review

References (51)

1. Bothamley G.H., Grange J.M. The Koch phenomenon and delayed hypersensitivity: 1891-1991. Tubercle 1991, 72:7-11.
2. Landsteiner K., Chase M.W. Studies on the sensitization of animals with simple chemical compounds: IX. Skin sensitization induced by injection of conjugates. J Exp Med 1941, 73:431-438.
3. Chase M.W., Landsteiner K. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc Soc Exp Biol Med 1942, 49:688-689.
4. Chase M.W. The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc Soc Exp Biol Med 1945, 59:134-135.
5. Freund J. The mode of action of immunologic adjuvants. Adv Tuberc Res 1956, 7:130-148.
6. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989, 54(Pt 1):1-13.
7. Adam A., Ellouz F., Ciorbaru R., Petit J.F., Lederer E. Peptidoglycan adjuvants: minimal structure required for activity. Z Immunitatsforsch Exp Klin Immunol 1975, 149:341-348.
8. Adam A., Petit J.F., Wietzerbin-Falszpan J., Sinay P., Thomas D.W., Lederer E. FEBS Lett 1969, 4:87-92.
9. Kobayashi S., Fukuda T., Yukimasa H., Fujino M., Azuma I., Yakamura Y. Synthesis of muramyl dipeptide analogs with enhanced adjuvant activity. Bull Chem Soc Jpn 1980, 53:2570-2577.
10. Philpott D.J., Sorbara M.T., Robertson S.J., Croitoru K., Girardin S.E. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 2014, 14:9-23.
11. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D.J., Sansonetti P.J. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003, 278:8869-8872.
12. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., Fukase K., Inamura S., Kusumoto S., Hashimoto M., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003, 278:5509-5512.
13. Raymond J.B., Mahapatra S., Crick D.C., Pavelka M.S. Identification of the namH gene, encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial peptidoglycan. J Biol Chem 2005, 280:326-333.
14. Ferwerda G., Girardin S.E., Kullberg B.J., Le Bourhis L., de Jong D.J., Langenberg D.M., van Crevel R., Adema G.J., Ottenhoff T.H., van der Meer J.W., Netea M.G. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 2005, 1:279-285.
15. Gandotra S., Jang S., Murray P.J., Salgame P., Ehrt S. NOD2-deficient mice control infection with Mycobacterium tuberculosis. Infect Immun 2007, 75:5127-5134.
16. Divangahi M., Mostowy S., Coulombe F., Kozak R., Guillot L., Veyrier F., Kobayashi K.S., Flavell R.A., Gros P., Behr M.A. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 2008, 181:7157-7165.
17. Coulombe F., Divangahi M., Veyrier F., de L.L., Gleason J.L., Yang Y., Kelliher M.A., Pandey A.K., Sassetti C.M., Reed M.B., Behr M.A. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 2009, 206:1709-1716.
18. Hansen J.M., Golchin S.A., Veyrier F.J., Domenech P., Boneca I.G., Azad A.K., Rajaram M.V., Schlesinger L.S., Divangahi M., Reed M.B., Behr M.A. N-glycolylated peptidoglycan contributes to the immunogenicity but not pathogenicity of Mycobacterium tuberculosis. J Infect Dis 2014, 209:1045-1054.
19. Pandey A.K., Yang Y., Jiang Z., Fortune S.M., Coulombe F., Behr M.A., Fitzgerald K.A., Sassetti C.M., Kelliher M.A. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog 2009, 5:e1000500.
20. Coulombe F., Fiola S., Akira S., Cormier Y., Gosselin J. Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection. PLoS ONE 2012, 7:e36734.
21. Comas I., Coscolla M., Luo T., Borrell S., Holt K.E., Kato-Maeda M., Parkhill J., Malla B., Berg S., Thwaites G., et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 2013, 45:1176-1182.
22. Donoghue H.D., Spigelman M., Greenblatt C.L., Lev-Maor G., Bar-Gal G.K., Matheson C., Vernon K., Nerlich A.G., Zink A.R. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect Dis 2004, 4:584-592.
23. Comas I., Chakravartti J., Small P.M., Galagan J., Niemann S., Kremer K., Ernst J.D., Gagneux S. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010, 42:498-503.
24. Corbett E.L., Marston B., Churchyard G.J., De Cock K.M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367:926-937.
25. Thoma-Uszynski S., Stenger S., Takeuchi O., Ochoa M.T., Engele M., Sieling P.A., Barnes P.F., Rollinghoff M., Bolcskei P.L., Wagner M., et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001, 291:1544-1547.
26. Schlesinger L.S., Kaufman T.M., Iyer S., Hull S.R., Marchiando L.K. Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J Immunol 1996, 157:4568-4575.
27. Ishikawa E., Ishikawa T., Morita Y.S., Toyonaga K., Yamada H., Takeuchi O., Kinoshita T., Akira S., Yoshikai Y., Yamasaki S. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 2009, 206:2879-2888.
28. Kleinnijenhuis J., Quintin J., Preijers F., Joosten L.A., Ifrim D.C., Saeed S., Jacobs C., van L.J., De J.D., Stunnenberg H.G., et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012, 109:17537-17542.
29. Austin C.M., Ma X., Graviss E.A. Common nonsynonymous polymorphisms in the NOD2 gene are associated with resistance or susceptibility to tuberculosis disease in African Americans. J Infect Dis 2008, 197:1713-1716.
30. Zhang F.R., Huang W., Chen S.M., Sun L.D., Liu H., Li Y., Cui Y., Yan X.X., Yang H.T., Yang R.D., et al. Genomewide association study of leprosy. N Engl J Med 2009, 361:2609-2618.
31. Pan H., Dai Y., Tang S., Wang J. Polymorphisms of NOD2 and the risk of tuberculosis: a validation study in the Chinese population. Int J Immunogenet 2012, 39:233-240.
32. Berrington W.R., Macdonald M., Khadge S., Sapkota B.R., Janer M., Hagge D.A., Kaplan G., Hawn T.R. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J Infect Dis 2010, 201:1422-1435.
33. Grant A.V., Alter A., Huong N.T., Orlova M., Van T.N., Ba N.N., Thai V.H., Abel L., Schurr E., Alcais A. Crohn's disease susceptibility genes are associated with leprosy in the Vietnamese population. J Infect Dis 2012, 206:1763-1767.
34. Mahapatra S., Crick D.C., McNeil M.R., Brennan P.J. Unique structural features of the peptidoglycan of Mycobacterium leprae. J Bacteriol 2008, 190:655-661.
35. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
36. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
37. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., Lee J.C., Schumm L.P., Sharma Y., Anderson C.A., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
38. Abel L., Alcais A., Schurr E. The dissection of complex susceptibility to infectious disease: bacterial, viral and parasitic infections. Curr Opin Immunol 2014, 30C:72-78.
39. Feller M., Huwiler K., Stephan R., Altpeter E., Shang A., Furrer H., Pfyffer G.E., Jemmi T., Baumgartner A., Egger M. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007, 7:607-613.
40. Behr M.A., Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr Opin Gastroenterol 2008, 24:17-21.
41. Simeone R., Bobard A., Lippmann J., Bitter W., Majlessi L., Brosch R., Enninga J. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog 2012, 8:e1002507.
42. Manzanillo P.S., Shiloh M.U., Portnoy D.A., Cox J.S. Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. Cell Host Microbe 2012, 11:469-480.
43. Brooks M.N., Rajaram M.V., Azad A.K., Amer A.O., Valdivia-Arenas M.A., Park J.H., Nunez G., Schlesinger L.S. NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages. Cell Microbiol 2011, 13:402-418.
44. Pandey R.K., Sodhi A., Biswas S.K., Dahiya Y., Dhillon M.K. Mycobacterium indicus pranii mediates macrophage activation through TLR2 and NOD2 in a MyD88 dependent manner. Vaccine 2012, 30:5748-5754.
45. Herskovits A.A., Auerbuch V., Portnoy D.A. Bacterial ligands generated in a phagosome are targets of the cytosolic innate immune system. PLoS Pathog 2007, 3:e51.
46. Nakamura N., Lill J.R., Phung Q., Jiang Z., Bakalarski C., de M.A., Klumperman J., Schlatter M., Delamarre L., Mellman I. Endosomes are specialized platforms for bacterial sensing and NOD2 signalling. Nature 2014, 509:240-244.
47. Ferwerda G., Kullberg B.J., de Jong D.J., Girardin S.E., Langenberg D.M., van Crevel R., Ottenhoff T.H., van der Meer J.W., Netea M.G. Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2. J Leukoc Biol 2007, 82:1011-1018.
48. Leber J.H., Crimmins G.T., Raghavan S., Meyer-Morse N.P., Cox J.S., Portnoy D.A. Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen. PLoS Pathog 2008, 4:e6.
49. Magalhaes J.G., Fritz J.H., Le B.L., Sellge G., Travassos L.H., Selvanantham T., Girardin S.E., Gommerman J.L., Philpott D.J. Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 2008, 181:7925-7935.
50. Juarez E., Carranza C., Hernandez-Sanchez F., Leon-Contreras J.C., Hernandez-Pando R., Escobedo D., Torres M., Sada E. NOD2 enhances the innate response of alveolar macrophages to Mycobacterium tuberculosis in humans. Eur J Immunol 2012, 42:880-889.
51. Schenk M., Krutzik S.R., Sieling P.A., Lee D.J., Teles R.M., Ochoa M.T., Komisopoulou E., Sarno E.N., Rea T.H., Graeber T.G., et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med 2012, 18:555-563.